Hepatitis B reactivation following switch away from tenofovir-containing anti-retroviral therapy in people living with HIV: A case series and lessons for practice

2025/11/17 by Flora Olcott, Philip D Oddie, Maeve J Barlow +10 · 1 voice
Medicine · #HIV/AIDS drug development and treatment #Hepatitis B Virus Studies #Hepatitis C virus research

paper · doi:10.1093/cid/ciaf634

openalex publication_date 2025/11/17 · openalex created_date 2025/11/20 · openalex updated_date 2026/08/01

Abstract

The potential for hepatitis B reactivation must be considered when switching people with HIV and prior hepatitis B exposure away from tenofovir-containing combined anti-retroviral therapy. Four cases of hepatitis B reactivation from the United Kingdom are presented. Hepatitis B mutations, risk factors and pre- and post-switch recommendations are explored.

Discussions

• #HepatitisB #reactivation in people living with #HIV when switched off #tenofovir... could become more of an issue as we move to dual #treatment and long-acting HIV regimens. #MedSky #IDSky #HIVSky [bsky, 2 points, 0 comments]

Related

• To Switch or not to Switch to Long-acting Injectable Cabotegravir/Rilpivirine in PWH With Past Hepatitis B Virus (HBV) Coinfection: Which HBV Markers to Manage Risk of HBV Reactivation?
• Incidence and Outcome of Hepatitis D Virus Infection in People With HIV and Hepatitis B Virus Coinfection in the Era of Tenofovir-Containing Antiretroviral Therapy
• Hepatitis B virus reactivation during cytotoxic chemotherapy‐enhanced viral replication precedes overt hepatitis
• Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection
• Hepatitis B Virus Reactivation in Non‐Liver Solid Organ Transplantation: Incidence and Risk Analysis